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Key Points




Platelet reactivity via
the PAR-1 thrombin
receptor is mediated
by GRK5.
Platelet GRK5 is
associated with
thrombus formation in
humans and mice.

The interindividual variation in the functional response of platelets to activation by agonists
is heritable. Genome-wide association studies (GWASs) of quantitative measures of platelet
function have identiﬁed fewer than 20 distinctly associated variants, some with unknown
mechanisms. Here, we report GWASs of pathway-speciﬁc functional responses to agonism
by adenosine 59 -diphosphate, a glycoprotein VI–speciﬁc collagen mimetic, and thrombin
receptor-agonist peptides, each speciﬁc to 1 of the G protein–coupled receptors PAR-1 and
PAR-4, in subsets of 1562 individuals. We identiﬁed an association (P 5 2.75 3 10240)
between a common intronic variant, rs10886430, in the G protein–coupled receptor kinase 5
gene (GRK5) and the sensitivity of platelets to activate through PAR-1. The variant resides in
a megakaryocyte-speciﬁc enhancer that is bound by the transcription factors GATA1 and
MEIS1. The minor allele (G) is associated with fewer GRK5 transcripts in platelets and the
greater sensitivity of platelets to activate through PAR-1. We show that thrombin-mediated
activation of human platelets causes binding of GRK5 to PAR-1 and that deletion of the
mouse homolog Grk5 enhances thrombin-induced platelet activation sensitivity and
increases platelet accumulation at the site of vascular injury. This corroborates evidence
that the human G allele of rs10886430 is associated with a greater risk for cardiovascular
disease. In summary, by combining the results of pathway-speciﬁc GWASs and expression
quantitative trait locus studies in humans with the results from platelet function studies in
Grk52/2 mice, we obtain evidence that GRK5 regulates the human platelet response to
thrombin via the PAR-1 pathway.

Submitted 4 June 2021; accepted 12 July 2021; prepublished online on Blood
Advances First Edition 28 September 2021; ﬁnal version published online 5 April
2022. DOI 10.1182/bloodadvances.2021005453.
*K.D., X.Z., W.J.A., and P.M. contributed equally to this work.
Data sharing requests should be sent to Kate Downes (kate.downes@addenbrookes.
nhs.uk).
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Introduction
Platelets are essential to prevent bleeding. By continuously surveying vessel walls and activating in response to damage, they initiate
the formation of thrombi to close any breaches. If hemostasis is well
balanced, thrombus formation is followed by thrombolysis and vessel wall repair. Unfortunately, platelet activation may initiate inappropriate thrombus formation in individuals with vascular disease,
leading to vessel occlusion and ischemia. Consequently, platelet
inhibitors are standard treatment for the secondary prevention and
treatment of ischemic cardiovascular diseases.

Here, we present the results of GWASs of platelet reactivity phenotypes in subsets of 1562 healthy adults who were enrolled in
the Cambridge Platelet Function Cohort (PFC). Using ﬂow cytometry, we measured responses to agonism by ADP, by the GPVIspeciﬁc ligand collagen-related peptide (CRP-XL), and by thrombin
receptor-agonist peptides, each speciﬁc to PAR-1 or PAR-4. Analyses of these phenotypes replicated several known pathwayspeciﬁc associations. Additionally, we identiﬁed an association, on
chromosome 10q26, between a variant in a platelet expression
quantitative trait locus (eQTL) for G protein–coupled receptor
kinase 5 gene (GRK5) and reactivity to thrombin, replicating a
recently published association in which reactivity was measured by
LTA.10 By analyzing reactivity to PAR-1– and PAR-4–speciﬁc peptides, we provide compelling evidence that the association signal
in GRK5 is mediated through the PAR-1 receptor. Furthermore, by
deleting the mouse homolog Grk5, we show that mouse platelets
without Grk5 exhibit greater ex vivo platelet reactivity to thrombin,
but not to other agonists. Grk52/2 mice showed greater platelet
accumulation upon laser-induced vascular injury and increased
thrombin-induced pulmonary thromboembolism compared with
wild-type (WT) controls. Collectively, the results of our genetic and
functional studies in humans and mice provide robust evidence
that G protein-coupled receptor kinase 5 (GRK5) encoded by
GRK5, is a key regulator of platelet activation by thrombin via the
G protein–coupled receptor (GPCR) PAR-1.
2320
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Detailed descriptions of the materials and methods used are provided in supplemental Information.

Human study participants
Donors registered with National Health Service Blood and Transplant (NHSBT) were invited to join the National Institute for Health
Research BioResource, a cohort of volunteers who have consented
to be recalled for studies by genotype. Subsequently, these NIHR
BioResource members were invited to participate in the Cambridge
PFC. Blood for the protein binding experiments was provided by
healthy donors at Thomas Jefferson University. Written informed
consent was obtained from participants prior to blood collection.
Information about the study participants and the permissions of the
institutional review board and research ethics committee are provided in supplemental Information.

Platelet function association study
DNA extracted from EDTA-treated blood from Cambridge PFC participants was genotyped using the UK Biobank Axiom Array
(Thermo Fisher, Santa Clara, CA). A description of the quality control and imputation methods is included in supplemental Information.
Platelet activation was measured by whole blood ﬂow cytometry
assays, as previously described11 (supplemental Information). Platelets were agonized with ADP (Sigma-Aldrich), CRP-XL (crosslinked
monomeric sequence GCO[GPO]10GCOG; Department of Biochemistry, University of Cambridge), PAR-1, PAR-4,12 and TRAP-6
(Tocris) agonist peptides. The binding of a PE-labeled anti–Pselectin monoclonal antibody (CD62P; NHSBT, Bristol, UK) and
FITC-labeled polyclonal anti-ﬁbrinogen (Agilent Dako) was quantiﬁed
using Beckman Coulter ﬂow cytometers. Individual-level summaries
of platelet reactivity were derived by logit transforming the percentage of cells with a signal greater than a threshold determined from
background, measured in corresponding aliquots of unagonized
blood.
PLT# and MPV were measured from EDTA-treated blood using
Beckman Coulter and Sysmex Complete Blood Count analyzers.
We regressed the variation explained by sex, age, PLT#, MPV, and
reagent batch from the individual-level summaries of reactivity (supplemental Information).
With the exception of 1 subset of 450 individuals for whom the activation response to agonism by ADP was measured in duplicate only
by ﬁbrinogen binding, each activation response was measured 4
times: twice using P-selectin expression and twice using ﬁbrinogen
binding. Outliers and discordant repeated measurements were discarded, and the average of the repeats was taken. The effect of
PLT#, MPV, sample batch, sex, and age were regressed out of
each average. Outliers and samples for which the P-selectin and
ﬁbrinogen binding averages were discordant were discarded. The
P-selectin expression and ﬁbrinogen binding averages correlated
strongly (supplemental Figure 1); therefore, to increase the power to
detect novel genetic associations, we performed a GWAS for each
agonist using the score vector corresponding to the ﬁrst principal
component of the averaged P-selectin and averaged ﬁbrinogen
measurements as the phenotype, after further adjustment for PLT#,
MPV, sample batch, sex, age, and time elapsed between the start
of the study and the time of measurement. The GWAS tests were
12 APRIL 2022 • VOLUME 6, NUMBER 7
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Measures of the activation sensitivity of platelets, henceforth
“reactivity phenotypes,” have heritable interindividual components of
variation.1,2 However, this heritable variation is less well studied than
that of resting platelet phenotypes, such as platelet count (PLT#)
and mean platelet volume (MPV). Genome-wide association studies
(GWASs) of platelet phenotypes measured by complete blood
counts (CBC) in more than half a million participants identiﬁed
.1800 distinctly associated genetic variants, explaining much of
the heritable variation in the population with European ancestry.3,4 In
contrast, studies designed to identify variants associated with platelet reactivity by agonists have each relied on ,4000 participants
and, in aggregate, identiﬁed ,20 distinctly associated alleles.2,5-9
The principal reason for relatively low sample sizes is the intricate
nature of platelet reactivity phenotyping. The activation of platelets in
response to vascular damage is caused by the binding of a variety
of agonists to cell surface receptors, in particular, the receptors for
collagen and thrombin, which are important initiators of activation,
and the receptors for adenosine 59 -diphosphate (ADP) and thromboxane A2, which are important for ampliﬁcation. To quantify reactivity in vitro, these receptors must be stimulated and the platelet
response measured by light transmission aggregometry (LTA) or by
ﬂow cytometry of surface markers of activation.

Methods

performed using linear mixed models to control for relatedness. For
response to agonism by ADP, separate GWASs were performed in
the subset of individuals for whom reactivity was measured by ﬁbrinogen binding only, as well as in the subset for whom reactivity was
measured by ﬁbrinogen binding and P-selectin expression. The evidence for association was combined using inverse variance
weighted meta-analysis after scaling the statistics from the ﬁbrinogen binding GWAS to place them on the same scale of measurement as the statistics from the other GWAS.

A detailed description of the genetic association analysis is provided
in supplemental Information.

GRK5 and PAR-1 immunoprecipitation
Washed human platelets were activated using thrombin and then
lysed (supplemental Information). Proteins were precipitated with an
anti–PAR-1 (ATAP-2) antibody or inert control immunoglobulin and
probed for GRK5 before reprobing with an anti–PAR-1 antibody.

Mouse models
All mouse protocols were approved by the Institutional Animal Care
and Use Committee of the University of Pennsylvania or Thomas Jefferson University.
Mice protocols are described in supplemental Information. Grk5knockout mice were generated on a C57BL/6 background using
CRISPR-Cas9 genome editing14; fetal liver chimeras were generated using transplantation from WT control or Grk52/2 mice.

Agonist-mediated platelet activation in vitro
Mouse platelet activation experiments were performed as described
previously using ﬂow cytometry and LTA15 (supplemental Information). For ﬂow cytometry, platelets were stimulated with PAR-4 agonist peptide (PAR-4–AP), ADP, thromboxane A2 mimetic (U46619),
or convulxin in diluted heparinized blood. Binding of ﬂuorochromeconjugated antibodies against CD41, P-selectin (CD62P; BD
Bioscience), and activated integrin was used to measure platelet
activation with a BD LSR II Flow Cytometer (BD Biosciences). For
LTA assays, platelets were collected from platelet-rich plasma, and
counts were adjusted to 2 3 108 per milliliter. Aggregation was
observed in a PAP-8E Platelet Aggregation Proﬁler (Bio/Data Corporation). Single end point luminescence assays were used to
quantify agonist-induced platelet ATP release, as described.15

Vascular injury and pulmonary
thromboembolism models
Thrombus formation upon vascular injury was measured in the cremaster muscle microcirculation of 8- to 12-week-old male mice, as
described.16 Pulmonary thromboembolism assay was performed as
previously described with some modiﬁcations.17 Additional details
about each method are provided in supplemental Information. Data
sets were compared using the Student t test or the Mann-Whitney
U test. P #. 05 was considered statistically signiﬁcant.
12 APRIL 2022 • VOLUME 6, NUMBER 7

GWASs for platelet activation
We measured platelet reactivity to agonists in subsets of 1562
healthy participants in the Cambridge PFC using pathwayspeciﬁc ex vivo stimulation. We agonized the platelet GPCR
signaling pathways, activating the receptors P2Y1 and P2Y12
with ADP and PAR-1 and PAR-4 (the thrombin receptors) with
receptor-speciﬁc peptides (PAR-1 and PAR-4). Additionally, we
agonized the GPVI-Fc«RI/ITAM signaling pathway with CRP-XL.
We quantiﬁed platelet reactivity at the individual level by summarizing cell level measurements of surface P-selectin expression
and bound ﬁbrinogen.
GWAS identiﬁed 5 genome-wide signiﬁcant association signals
(P , 5 3 1028; Figure 1; Table 1). These association signals recapitulate previous studies, including those by us based on analyses
of subsets of the present data set. They include associations with
reactivity to ADP in PEAR1 (rs12566888) and ARHGEF3
(rs7624918) and associations with reactivity to CRP-XL in GP6
(rs1613662).2,9,11 The analyses of reactivity to the 2 thrombin
receptor agonists relied on entirely new data and identiﬁed 2 associations. First, we replicated an association in F2RL3 (rs773902), the
gene encoding the PAR-4 receptor, identiﬁed with reactivity to
PAR-4 agonism measured by LTA.18 Second, we identiﬁed a
newly discovered association in GRK5 (rs10886430, chr10:
121010256A.G, GRCh37) with reactivity to PAR-1 agonism.10
The PAR-1 association signal in the GRK5 locus was explained
completely by conditioning on the imputed minor allele (G)
count of rs10886430, the variant exhibiting the strongest evi^ 5 1.09
dence for association with platelet reactivity (n 5 546; b
standard deviations [SDs]; standard error [SE], 8.21 3 1022;
P 5 2.75 3 10240; Figure 2A; Table 1). Our analyses showed
that rs10886430 is not associated with platelet activation by
ADP or CRP-XL. However, an association was identiﬁed with
reactivity to the PAR-4–speciﬁc peptide, although with a smaller
^ 5 0.44 SD; SE, 0.092; P 5 2.20 3
estimated effect size (b
26
10 ) (supplemental Figure 3).
We replicated the association with rs10886430, in the same study
participants, by replacing the PAR-1 agonizing peptide with TRAP-6,
another PAR-1 receptor–speciﬁc agonist peptide (b^ 5 1.18 SD; SE,
0.0801; P 5 8.91 3 10249). Additionally, we performed an out-ofsample replication experiment using the TRAP-6 agonist and a
microplate-based platelet aggregation assay,13 which provided evidence for an association with the same direction of effect (n 5 253;
b^ 5 20.103 SD; SE, 0.042; P 5 .014; supplemental Figure 4).

Genomic characterization of PAR-1 platelet
activation association at GRK5
To explore the molecular mechanism underlying the platelet reactivity association at GRK5, we interrogated eQTL data for platelets
aggregated from 2 independent studies (supplemental Information).
The minor allele (G) of rs10886430, corresponding to greater platelet reactivity, was associated with a lesser amount of GRK5 messenger RNA in platelets (n 5 388; b^ 5 20.50 SD; SE, 0.0473;
P 5 4.79 3 10223; Figure 2B).
Inspection of our previously published erythroblast and megakaryocyte (MK) assay for transposase-accessible chromatin with highGRK5 REGULATES THROMBIN SIGNALING IN PLATELETS
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For replication, platelet activation was measured in an independent
cohort of donors using a plate-based aggregation end point assay,
as described.13 The aggregation of platelets in response to increasing doses of TRAP-6 was measured using absorbance, and curves
were generated to calculate the 50% effective concentration values.

Results
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Figure 1. Genome-wide associations with platelet reactivity. Manhattan plot showing the P values of tests for association between genetic variants and each of 4
phenotypes measuring the reactivity of platelets to agonism by ADP, CRP-XL, PAR-1, and PAR-4 in the Cambridge PFC. Each dot corresponds to a genetic variant in the
Haplotype Reference Consortium r1.1 reference panel. The position on the x-axis indicates the physical position of the variant; the position on the y-axis indicates the -log10
P value of a Wald test for association from a linear mixed-model (on a log scale). Only variants with an imputation INFO score . 0.6 and a P value , .1 are shown. The
horizontal dashed line corresponds to the genome-wide signiﬁcance threshold (5 3 1028). The red dots correspond to the variants showing the strongest evidence for
association in those loci containing signiﬁcantly associated variants. The red gene names indicate the gene causally mediating each of these associations.

throughput sequencing (ATAC-seq) data showed that rs10886430
lies in an MK-speciﬁc nucleosome-depleted element.9 Chromatin
immunoprecipitation and sequencing (ChIP-seq) of MKs showed
that the element has the H3K27Ac proﬁle characteristic of an
enhancer and identiﬁed strong evidence for binding by GATA1 and
MEIS1, 2 of the key MK lineage transcription factors.9 However, we
did not see any evidence for binding by the MK factors FLI1,
GATA2, RUNX1, and TAL119,20 (Figure 2C). A difference in afﬁnity
between the 2 alleles of rs10886430 to bind to GATA1 and/or
MEIS1 is the most likely explanation for the GRK5 eQTL. This
hypothesis is supported by Rodriguez et al, who showed that the

transcriptional activity of constructs containing the enhancer region
is reduced when the G allele of rs10886430 is introduced into
K562 cell and HUVEC lines.10
Together, these ﬁndings indicate that the molecular mechanism
explaining the association between rs10886430 and platelet reactivity to agonism through PAR-1 is mediated by the allele-speciﬁc
differences in the expression of GRK5 messenger RNA.

Binding of GRK5 to PAR-1 during platelet activation
The regulation of PAR-1 signaling by GRK5 suggests that
GRK5 binds to PAR-1 in response to thrombin stimulation. To
28

Table 1. Summary statistics for platelet-reactivity genome wide association study (,5 3 10
Chr

Position

Predicted
consequence

ADP

rs12566888

1

156 869 047

Intronic variant

G

T

0.09

1341

20.391

0.0706

ADP

rs7624918

3

56 901 292

Intronic variant

C

T

0.34

1341

0.284

0.0434

5.75 3 10211

ARHGEF3

CRP-XL

rs1613662

19

55 536 595 Nonsynonymous variant
c.655C.T
p.(Pro219Ser)

G

A

0.83

1329

0.923

0.0432

5.01 3 102101

GP6

PAR-4

rs773902

19

17 000 632 Nonsynonymous variant
c.358G.A
p.(Ala120Thr)

G

A

0.20

550

0.515

0.0698

1.66 3 10213

F2RL3

PAR-1

rs10886430

10

A

G

0.13

546

1.09

0.0821

2.75 3 10240

GRK5

Phenotype

121 010 256

Intronic variant

Ref.
Alt. allele
allele Alt. allele frequency

)

Variant
ID

n

Effect size
SE
(SD/ALT allele) (SD/ALT alleles)

Coordinates are based on GRCh37. Predicted consequences are based on GP6 transcript NM_001083899.2 and PAR-4 transcript NM_003950.4
Alt., alternative; Chr, chromosome; Ref., reference.
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Figure 2. Increased platelet reactivity via PAR-1 at rs10886430 is due to decreased expression of GRK5. Box plots showing the relationships between the
genotype of rs10886430 and the reactivity of platelets to PAR-1 (after adjustment for covariates) in 546 participants in the Cambridge PFC (A) and platelet expression of
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Figure 3. Activation of platelets with thrombin increases GRK5 and PAR-1 binding in human platelets. (A) Resting human platelets or thrombin
(1 U/mL)-activated platelets were prepared and lysed. Proteins were precipitated with an anti–PAR-1 (ATAP-2) antibody or control immunoglobulin (Ig) and then probed
with anti-GRK5 antibody and reprobed with an anti–PAR-1 antibody (n 5 6). (B) Lysates from resting or activated platelets were precipitated with an anti-GRK5 antibody
or Ig and probed with anti–PAR-1 before reprobing with anti-GRK5 (n 5 3). IB, immunoblotting; IP, immunoprecipitation; ns, not signiﬁcant.

evaluate this interaction, we precipitated these proteins in
washed human platelets and then probed them using antibodies against GRK5 or PAR-1 (Figure 3). During platelet
activation using thrombin (1 U/mL), immunoprecipitation of
PAR-1 coprecipitated GRK5 (Figure 3A); conversely, immunoprecipitation of GRK5 pulled down PAR-1 (Figure 3B). Furthermore,
when platelets were activated with a lower concentration of
thrombin (0.1 U/mL), immunoprecipitation of GRK5 also pulled
down PAR-1 (supplemental Figure 5). When we applied the
same experimental procedure to resting platelets, we detected little or no binding of GRK5 to PAR-1. GRK5 and GRK6 are 72%
homologous at the amino acid level21,22; therefore, we excluded

the possibility that our results were a consequence of crossreactivity between anti-GRK5 and GRK6 (supplemental Figure 6).

Generation and characterization of Grk52/2 mice
We studied the consequences of Grk5 inhibition on thrombinmediated activation signaling using Grk5-knockout mice. Grk52/2
mice were generated by introducing a premature stop codon using
CRISPR-Cas9, resulting in the loss of Grk5 expression (supplemental
Figure 7). Grk52/2 mice that were generated by crossing were born
in the expected Mendelian inheritance ratios and were viable and
grossly normal in appearance. The average values of CBC-measured
hematological variables did not differ signiﬁcantly between knockout

Figure 2 (continued) GRK5 measured using probe ID:3190239 of the Illumina HumanHT-12 v4.0 Expression BeadChip microarray in 388 donors (B), after adjustment for
technical variation. The thick horizontal bars indicate the median of each conditional distribution and the lower and upper hinges indicate the 25th and 75th percentiles,
respectively, of each distribution. The whiskers extend no further than 1.5 interquartile ranges from the hinges. (C) The genetic association between PAR-1 reactivity and
rs10886430 in intron 1 of GRK5 colocalizes with the binding of the transcription factors GATA-1 and MEIS1 in human MKs and an enhancer speciﬁc to the human MK
blood cell lineage. Top to bottom: the strength of evidence for the association between genetic variants in the GRK5 locus and PAR-1 reactivity, measured by 2log10(P
value); the binding sites of the transcription factors GATA-1, RUNX1, FLI1, and MEIS1 in human MKs; ATAC-seq read depth indicating regions of open chromatin in human
MKs; ChIP-seq read depth measuring the histone modiﬁcations H3K4me1, HSK4me3, and H3K27ac in human MKs; human MK enhancer sites inferred from the ATAC-seq
and ChIP-seq data; and a model of the GRK5 gene with exons indicated by rectangles.
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mice and their WT littermates (supplemental Table 1). Furthermore,
deletion of Grk5 did not affect the expression of Grk2 and Grk6 proteins in mouse brain (supplemental Figure 7D).

Grk52/2 platelets display increased agonistmediated platelet activation ex vivo

We used single end point luminescence assays15 to measure the
ATP released from platelets in response to agonism by Par-4 agonist peptide and ADP. Increased ATP release was observed in platelets from Grk52/2 mice compared with WT mice upon activation
using a low dose of Par-4 agonist peptide (P 5 .04). However,
there was no evidence for a difference in the response to agonism
by ADP (supplemental Figure 10). These results are compatible
with the notion that platelets without Grk5 secrete a greater number
of d-granules when activated via the thrombin receptor Par-4 compared with normal WT platelets (Figure 4E).
ADP activates platelets by binding to Gq-coupled P2Y1 and Gi2coupled P2Y12 receptors.24 ADP P2Y12 signaling triggers activation/
phosphorylation of the Gi2-mediated serine/threonine kinase Akt.25
To determine whether deletion of Grk5 affects P2Y12-dependent
signaling, we compared phosphorylation of Akt in WT and Grk52/2
platelets in response to ADP stimulation in the presence or absence
of the P2Y1 antagonist (MRS2500) or the P2Y12 antagonist (cangrelor) (supplemental Information). Upon ADP stimulation, Grk52/
2
platelets exhibited greater phosphorylation of Akt than did WT
platelets, but the increase was not statistically signiﬁcant (supplemental Figure 11). Greater phosphorylation of Akt from Grk52/2
platelets vs WT platelets was still observed upon blocking P2Y1
with MRS2500 (supplemental Figure 11C). However, in the presence of the P2Y12 antagonist cangrelor, the phosphorylation of
Akt in response to stimulation by ADP was abolished in WT and
Grk52/2 platelets (supplemental Figure 11A).

Grk5 regulates the hemostatic response to
injury in vivo
We used the laser-induced injury model in cremaster muscle arterioles to investigate whether enhanced in vitro platelet responsiveness
12 APRIL 2022 • VOLUME 6, NUMBER 7

Absence of Grk5 increases thrombin-induced
pulmonary thromboembolism
Finally, we evaluated the role of Grk5 in thrombin signaling using a
thrombosis model. Thrombin-induced pulmonary thromboembolism
is a model of systemic occlusive pulmonary microthrombi that are
composed of platelet aggregates and ﬁbrin.26,27 To determine
whether deletion of Grk5 would increase the incidence of thromboembolism formation induced by platelet activation, Grk52/2 mice
and their WT control littermates were injected IV with thrombin. In
the absence of Grk5, there was a 1.6-fold increase in thrombus formation in the lung of Grk52/2 mice compared with their WT control
littermates (Figure 5F-G).

Discussion
We performed GWAS analyses of platelet reactivity phenotypes in
subsets of 1562 healthy blood donors, recapitulating genetic association signals previously reported by us and by other investigators
(in ARHGEF3 and PEAR1 for ADP, in GP6 for CRP-XL, and in
F2RL3 for PAR-4–speciﬁc agonist peptide). Additionally, we identiﬁed a new association between the variant rs10886430 in GRK5
and platelet reactivity to a PAR-1 agonist peptide, corroborating the
recent report of an association with platelet reactivity to thrombin
measured by LTA.10 Our analyses clariﬁed the molecular mechanism distal to the allelic variation in GRK5. The direct consequence
of the polymorphism almost certainly generates differential binding
afﬁnity of the transcription factors GATA1 and MEIS1 to an
MK-speciﬁc enhancer element, causing allelic differences in the
abundance of GRK5 transcript in platelets.
Interestingly, the association of rs10886430 with platelet reactivity
colocalizes with an association with MPV reported by Astle et al.4
The G allele, which is associated with lower platelet GRK5 transcript levels and greater platelet reactivity via PAR-1, is also
GRK5 REGULATES THROMBIN SIGNALING IN PLATELETS
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We compared the reactivity of platelets from Grk52/2 mice with
those from WT mice, using ﬂow cytometry to measure surfacebound ﬁbrinogen and anti–P-selectin as markers of aIIbb3 activation
and a-granule secretion respectively.15,23 We agonized platelets
using a mouse Par-4 thrombin receptor agonist peptide (AYPGKF),
because Par-4 is the mouse homolog of human PAR-1. Mean integrin activation (P 5 .04) and P-selectin expression (P 5 .01) were
greater in platelets generated by Grk52/2 than by WT mice in
response to a low-dose of the Par-4 agonist peptide. However,
there was no signiﬁcant difference when high doses of Par-4 agonist peptide were used (Figure 4A). There was no evidence for differences in activation response to agonism by ADP, by the
thromboxane A2 analog U46619, or by convulxin, which is an alternative ligand to CRP-XL for GpVI (supplemental Figure 8). Phenotyping of reactivity to the Par-4 agonist using LTA corroborated the
ﬂow cytometry data (Figure 4B). Furthermore, when platelets were
incubated with thrombin, an increased response was also observed
in Grk52/2 platelets (Figure 4C-D). LTA-measured responses to
other agonists indicated a slight initial increase in Grk52/2 platelet
response to ADP, but there was no difference in the response to
U46619 or convulxin (supplemental Figure 9).

to Par-4 receptor activation in Grk52/2 mice had an effect on thrombus formation following vascular damage.16,23 In this model, the
core of the hemostatic plug consists of P-selectin–positive platelets
bound by ﬁbrin that is surrounded by a loosely packed shell of lessactivated P-selectin–negative platelets. We measured platelet accumulation for 180 seconds following injury using ﬂuorescently labeled
anti-CD41 (Figure 5). Initially, platelets accumulated at similar rates
in Grk52/2 and WT mice (Figure 5A). However, we observed
greater accumulation at the late stage in Grk52/2 mice compared
with WT mice, as demonstrated by the increase in the mean area
under the curve (P 5 .03) and mean total platelet accumulation at
180 seconds postinjury (P 5 .016) (Figure 5B,D-E; supplemental
Figure 12). Because there was no difference in mean P-selectin
deposition between the 2 groups (supplemental Figure 13),
increased thrombus formation was due to an expansion of the
P-selectin–negative shell region, rather than the P-selectin–positive
core region. Deleting Grk5 did not affect ﬁbrin accumulation, suggesting that thrombin generation at the site of injury is normal in
Grk52/2 mice (supplemental Figure 13). To exclude possible effects
of Grk5 deletion on cells within the vascular wall, we performed
additional laser injury studies in irradiated WT mice reconstituted
with hematopoietic cells harvested from WT or Grk52/2 fetal livers.
The results showed that the increase in platelet accumulation at the
site of vascular injury was similar in reconstituted Grk52/2 mice to
that seen in whole-body Grk52/2 mice (supplemental Figure 14).
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Figure 4. Increased integrin activation, a-granule exocytosis, aggregation, and ATP release in platelets from Grk52/2 mice. (A) Platelets from Grk52/2 and
littermate control (WT) mice were stained with antibodies to activate AIIbb3 (Jon/A; left panel) or P-selectin (right panel) and measured by ﬂow cytometry. Platelets were
stimulated with Par-4–AP (AYPGKF) (n 5 3). Platelet reactivity in response to Par-4–AP (n 5 5) (B), representative aggregation traces (C), and summarized data (D) for
platelets stimulated with thrombin (mean 6 SEM; n 5 3-6 mice at each tested concentration). (E) ATP release for platelets from Grk52/2 and littermate control mice (WT)
stimulated with Par-4–AP (AYPGKF). The results of 3 experiments (mean 6 SEM) are summarized. MFI, mean ﬂuorescence intensity; ns, not signiﬁcant.

associated with greater MPV (P 5 6.6 3 10218). To exclude the
possibility that the platelet reactivity effect is mediated entirely
through variation in platelet volume, we regressed MPV from the
phenotype prior to performing our GWAS.
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Rodriquez et al identiﬁed the same genetic variant, rs10886430,
associated with platelet reactivity to thrombin; by generating GRK5knockdown platelets derived from MK progenitor cell lines and using
a GRK5 inhibitor in human platelets, they showed that GRK5
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Figure 5. Increased platelet accumulation at the site of vascular injury in Grk52/2 mice. (A) Platelet accumulation was visualized by CD41 staining after laser
injuries in cremaster muscle arterioles and recorded using confocal intravital ﬂuorescence microscopy. (B) Area under CD41 vs time curve. (C) Peak of the CD411 area at
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regulates signaling primarily via PAR-4.10 In contrast, our study provides compelling evidence that GRK5 also regulates thrombin signaling via PAR-1. The platelet reactivity ﬂow cytometry measurement
in our study differs from the standard LTA because ampliﬁcation of
the main subsidiary activation pathways is inhibited by aspirin, hirudin, and apyrase, when activating platelets with PAR-speciﬁc peptides. Hence, we can examine the genome-wide association results
in a pathway-speciﬁc manner excluding effects brought about by
subsidiary activation. Furthermore, the association of PAR-1 is supported by coimmunoprecipitation of GRK5 with PAR-1 upon platelet
activation by thrombin. Although not at genome-wide signiﬁcance,
our results also suggest that rs10886430 is associated with platelet
reactivity via PAR-4. Together, these results likely indicate that, in
human platelets, thrombin signaling via PAR-1 and PAR-4 is regulated by GRK5. The current challenges for studying this pathway
are due to the lack of speciﬁc anti–PAR-4 antibodies. Future work
will look to elucidate the contribution of GRK5 regulation in human
platelet thrombin signaling once speciﬁc reagents are available.
In humans, the protease-activated GPCRs PAR-1 and PAR-4 are
the receptors for thrombin. Cleavage of their exodomains by thrombin releases tethered ligands, which bind in a cognate manner to
the receptor. The synthetic PAR-1 and PAR-4 agonist peptides
used in this study mimic this speciﬁc mode of receptor activation.
Low concentrations of thrombin initiate platelet activation via PAR-1,
which is quickly terminated. PAR-4 requires higher thrombin concentrations, resulting in a later activation response, but one that is
12 APRIL 2022 • VOLUME 6, NUMBER 7

sustained.15 Phosphorylation of the thrombin PAR receptors by
GPCR kinases, including GRK5, induces the GRK–b-arrestin cascade, resulting in the termination of signaling by the internalization
and destruction of the active receptor in the lysosomes. Studies
indicate that the signaling kinetics of PAR-1 and PAR-4 differ, at
least in part, as a result of the rate or extent of signaling-dependent
phosphorylation.28 Our results suggest that GRK5 levels and, thus,
receptor phosphorylation, in platelets may have a lesser effect on
PAR-4 than on PAR-1 receptor signaling, supporting the conclusions of these previous studies of receptor kinetics in human
platelets.
In contrast to human platelets, mouse platelets express Par-3 and
Par-4, but not Par-1. Thrombin signaling in mouse platelets is mediated by Par-3–facilitated cleavage of Par-4, which responds quickly
to thrombin stimulation. Thus, in the context of thrombin receptor
signaling, mouse Par-4 has similar kinetic properties to human
PAR-1.29 Our study shows that mice that are unable to express
Grk5 exhibit greater platelet activation sensitivity, principally downstream of Par-4–dependent signaling pathways. This observation is
consistent with the association of the human G allele of
rs10886430 with reduced levels of GRK5 transcripts and
increased platelet reactivity to a PAR-1–speciﬁc agonist peptide.
Recent data generated by us show that, like GRK5, GRK6 is
involved in PAR-1–mediated signaling in human platelets.15 In keeping with this observation, deletion of Grk6 in mice enhances Par4–dependent signaling. Thus, mouse Par-4 signaling is regulated by
GRK5 REGULATES THROMBIN SIGNALING IN PLATELETS
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Grk6 in a manner that is similar to human PAR-1.15 The change in
platelet reactivity, as measured by ﬂow cytometry and ATP release,
caused by knockout of Grk5 is less than that caused by knockout
of Grk6. This is likely due to the lower abundance of Grk5 vs Grk6
in mouse platelets (supplemental Figure 15).30,31

GRK5 is ubiquitously transcribed. It is expressed across the hematopoietic lineages and in endothelial cells.34 It is also expressed in
most of the tissues surveyed by the GTEx studies.35 The desensitization of GPCRs is not a mechanism that is unique to the MK lineage, and interactors of GRK5, which include transmembrane,
cytosolic, and nuclear GPCRs, as well as non-GPCR proteins, are
involved in multiple signaling pathways, including the cell cycle, apoptosis, cell motility, and inﬂammation pathways. This may explain
why variants in the GRK5 locus have been associated with many
biomedically relevant quantitative traits and disease risks affecting a
range of physiological systems. They include height, type 2 diabetes, lung function, and many neurological and behavioral traits, such
as the risk of alcohol misuse and posttraumatic depression. This
pleiotropy suggests that the therapeutic manipulation of GRK5
expression is likely to avoid off-target effects only if it can be
achieved with cell-type speciﬁcity. For example, GRK5 activity has
been shown to be increased in heart failure models and is under
investigation as a potential target for pharmacological inhibition.36
However, our results and those of Rodriquez et al imply that
inhibition of GRK5 in platelets would be prothrombotic and proinﬂammatory10. On the other hand, further investigation of the plateletspeciﬁc binding partners of GRK5 as candidate targets for novel
antithrombotic drugs may be warranted.
To conclude, by activating platelets through speciﬁc signaling pathways, we conﬁrmed previously published associations and identiﬁed
a new genetic association with platelet reactivity mediated via the
thrombin GPCR PAR-1 in GRK5. The platelet eQTL, epigenetic
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Inhibition of platelet activation is known to reduce the risk of secondary thrombotic ischemia in patients with vascular disease. Therefore, it seems reasonable to hypothesize that variations in the
sensitivity of platelets to activation by thrombin generates variations
in the population’s risks of thrombotic diseases. Indeed, the G allele
of rs10886430 has been associated with a greater risk for thrombotic disease in the 0.5 million participants in the UK Biobank, most
notably with regard to the risk of pulmonary embolism (odds ratio,
1.28; P 5 8.05 3 10213).32 Associations have also been identiﬁed
with the risk of venous thromboembolism in the INVENT Consortium
(odds ratio, 1.12; P 5 2.2 3 10212) and in the Million Veteran Program (P 5 6.7 3 10211).33 In addition, Mendelian randomization
analysis of individuals in the UK Biobank suggests a causal role for
thrombin-induced platelet reactivity in thrombotic disease, most
notably pulmonary embolism.10 The observation that Grk52/2 mice
exhibit more rapid platelet accumulation during in vivo thrombus formation upon vascular damage compared with WT mice supports
the hypothesis that these population associations are mediated
through variations in platelet reactivity. This suggests that associations with platelet reactivity, as measured by our in vitro assays, can
act as a good model for associations of platelet-mediated thrombotic pathologies of the venous circulation.

analyses of MKs, and functional work in human platelets and mice
evidence the molecular and biological mechanism mediated by the
inhibitory effect of GRK5 on PAR-1. This improves our understanding of the signaling pathways associated with thrombin signaling
and provides evidence for the distinct and wide-reaching consequences of dysregulation of GPCR-coupled receptor kinases.
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